Prøve GULL - Gratis
THE RISE AND RISE OF AYUSH
Healthcare Radius
|September 2023
The AYUSH sector has been experiencing significant growth in India. A focus on the trends in this sector, the demand drivers, and the way forward.
The phrase, 'a diamond in the rough' is an old Renaissance idiom that refers to something (or someone) with great potential but unimpressive at first glance. However, with the right refinement and exposure, it reveals its brilliance and mesmerizes others with its sparkling glory.
The ancient Indian treatments grouped today under the nomenclature of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy) present a similar tale of 'a diamond in the rough.' After staying low-profile for several decades after India's independence, the sector is exhibiting strong potential for recognition and growth.
According to a research report on the Ayush sector by the Forum on Indian Traditional Medicine (FITM) under Research and Information System for Developing Countries (RIS), the size of the Ayush market stood at $18.1 billion (Rs 1,49,451 crore) in 2020, growing from $2.85 billion (Rs 23,532 crore in 2014-15.
According to a report by the Research and Information. System for Developing Countries (RIS), 'Ayush Sector in India: Prospects & Challenges, the global market size of the herbal sector was about $657.5 billion (Rs 54,28,977 crore) in 2020. The total Ayush export of India has increased from $1.09 billion (Rs 9,000 crore) in 2014 to $1.54 billion (Rs 12,715 crore) in 2020. Another agency, Mordor Intelligence, estimates that the AYUSH industry in India is expected to reach Rs 1,82,400 crore by 2028, growing at an 8.6 percent CAGR from Rs 62,600 crore in 2022.
Role of the government
Denne historien er fra September 2023-utgaven av Healthcare Radius.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Healthcare Radius
Healthcare Radius
VENUS REMEDIES GETS DRUG APPROVALS IN VIETNAM
Venus Remedies, a fixed-dosage injectable manufacturer, has secured new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam.
1 mins
December 2025
Healthcare Radius
A HEALTHIER INDIA IN THE MAKING: LEADERS DECODE THE ROAD FROM 2025 TO 2026
The collective goal is clear and unanimous: to transition from a system that primarily treats sickness to one that actively promotes lifelong health and well-being.
12 mins
December 2025
Healthcare Radius
FROM GENES TO CARE: ADVANCING CLINICAL UNDERSTANDING OF HYPOPHOSPHATASIA
From genes to care, the story of hypophosphatasia reminds us that progress in medicine isn't only about scientific discovery, it's about turning knowledge into healing.
6 mins
December 2025
Healthcare Radius
ALEMBIC PHARMA GETS USFDA NOD FOR DILTIAZEM TABLETS IN THE US
Alembic Pharmaceuticals (Alembic) Aamour announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.
1 min
December 2025
Healthcare Radius
ZYDUS GETS USFDA APPROVAL FOR PROSTATE CANCER INJECTABLE
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).
1 min
December 2025
Healthcare Radius
SUPERHEALTH LAUNCHES HONEST SECOND OPINION FOR PATIENTS
Superhealth, a zero-wait, commission Superhealth, zerohospital network, announced the launch of \"Honest Second Opinion,\" a service that helps patients make informed decisions about their treatment plans and surgical recommendations.
1 min
December 2025
Healthcare Radius
KOTAK ALTS INVESTS RS 400MN IN MEDIVERSAL
Kotak Alternate Asset Managers (Kotak Alts), through its Kotak Life Science Fund I, which invests in early to growth-stage life sciences and healthcare businesses, has made an investment of Rs 400 million in Mediversal Healthcare.
1 min
December 2025
Healthcare Radius
INVIGA HEALTHCARE FUND ACQUIRES 21% STAKE IN FORUS HEALTH
Inviga Healthcare Fund (IHF), the private equity platform founded by Dr B. S. Ajaikumar of HCG, has acquired a 21 per cent stake in Forus Health, an ophthalmic diagnostics company whose devices have screened over 22 million patients across 75+ countries.
1 min
December 2025
Healthcare Radius
OPTIMISING MATERNITY OPS: REDUCING C-SECTION BURDEN THROUGH EVIDENCE-BASED PROTOCOLS
By building systems that support safety, documentation, and respectful care, institutions can improve outcomes, lower litigation risks, and strengthen quality scores, achieving what healthcare should truly represent: Care Through Trust.”
7 mins
December 2025
Healthcare Radius
MENTAL HEALTH CARE GOES DIGITAL WITH NEW THERAPY PLATFORM
Following the global observance and continuing the commitment to mental well-being, renowned clinical psychologist Kanika Jindal announced the launch of Harmony Therapy World, a holistic digital platform designed to bring emotional healing and psychological support to people everywhere, privately, compassionately, and without barriers.
1 min
December 2025
Translate
Change font size
